Related Experiment Videos
[Aspirin, oral anticoagulants, and heart failure]
1Service de cardiologie, CHU Pasteur, Nice.
Insights
Thromboembolic complications are rare in cardiac failure patients. Oral anticoagulants pose similar risks of bleeding and clotting, making their use controversial without further clinical trials.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Thromboembolic complications occur infrequently in patients with cardiac failure.
- Key risk factors include left ventricular mural thrombus, atrial fibrillation, low ejection fraction, and low peak oxygen consumption (VO2).
Purpose of the Study:
- To evaluate the controversy surrounding anticoagulant therapy in cardiac failure.
- To assess the risk-benefit ratio of oral anticoagulants in this patient population.
Main Methods:
- Review of existing literature on thromboembolism and anticoagulation in cardiac failure.
- Analysis of risk factors for thromboembolic events and cerebral hemorrhage.
Main Results:
- The risk of cerebral hemorrhage with oral anticoagulants is comparable to the risk of thromboembolism.
- Current evidence lacks large-scale clinical trials to definitively support anticoagulant use.
Conclusions:
- Anticoagulant therapy for cardiac failure remains controversial due to balanced risks.
- Risk stratification is recommended to identify patients who may benefit from anticoagulation pending further research.
Abstract:
The incidence of thromboembolic complications in patients with cardiac failure is low. The predisposing factors are principally the presence of a left ventricular mural thrombus, atrial fibrillation, a low ejection fraction and a low peak VO2. The risk of cerebral haemorrhage in a patient with cardiac failure treated with oral anticoagulants is about the same as the risk of thromboembolism. Therefore, anticoagulant therapy for patients with cardiac failure is controversial in the absence of a prospective large scale clinical trial demonstrating its benefits. In the meantime, a prudent approach with risk stratification to determine which patients would benefit the most from oral anticoagulation is advised.